- Home
- ACRS vs RLGT Comparison
ACRS vs RLGT Comparison
Compare ACRS & RLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | RLGT |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil Refining/Marketing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.2M | 291.6M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRS | RLGT |
|---|---|---|
| Price | $3.19 | $7.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $9.75 | $8.00 |
| AVG Volume (30 Days) | ★ 3.1M | 218.2K |
| Earning Date | 02-23-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.29 |
| Revenue | $15,742,000.00 | ★ $893,372,000.00 |
| Revenue This Year | N/A | $3.77 |
| Revenue Next Year | N/A | $3.51 |
| P/E Ratio | ★ N/A | $25.28 |
| Revenue Growth | N/A | ★ 4.04 |
| 52 Week Low | $1.05 | $5.44 |
| 52 Week High | $4.89 | $8.50 |
Technical Indicators
Market Signals| Indicator | ACRS | RLGT |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 59.51 |
| Support Level | $3.25 | $7.11 |
| Resistance Level | $3.78 | $8.50 |
| Average True Range (ATR) | 0.25 | 0.34 |
| MACD | -0.06 | 0.09 |
| Stochastic Oscillator | 13.52 | 51.98 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.